These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 16834834

  • 1. Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies.
    Smugar SS, Schnitzer TJ, Weaver AL, Rubin BR, Polis AB, Tershakovec AM.
    Curr Med Res Opin; 2006 Jul; 22(7):1353-67. PubMed ID: 16834834
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.
    Birbara C, Ruoff G, Sheldon E, Valenzuela C, Rodgers A, Petruschke RA, Chang DJ, Tershakovec AM.
    Curr Med Res Opin; 2006 Jan; 22(1):199-210. PubMed ID: 16393445
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.
    Schnitzer TJ, Weaver AL, Polis AB, Petruschke RA, Geba GP, VACT-1 and VACT-2 (Protocols 106 and 150) Study Groups.
    J Rheumatol; 2005 Jun; 32(6):1093-105. PubMed ID: 15940774
    [Abstract] [Full Text] [Related]

  • 4. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial.
    Gibofsky A, Williams GW, McKenna F, Fort JG.
    Arthritis Rheum; 2003 Nov; 48(11):3102-11. PubMed ID: 14613272
    [Abstract] [Full Text] [Related]

  • 5. A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis.
    Dahlberg LE, Holme I, Høye K, Ringertz B.
    Scand J Rheumatol; 2009 Nov; 38(2):133-43. PubMed ID: 19165648
    [Abstract] [Full Text] [Related]

  • 6. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG, Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators.
    Arch Intern Med; 2005 Jan 24; 165(2):161-8. PubMed ID: 15668361
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and tolerability of sustained-release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double-blind, placebo-controlled study.
    Malonne H, Coffiner M, Sonet B, Sereno A, Vanderbist F.
    Clin Ther; 2004 Nov 24; 26(11):1774-82. PubMed ID: 15639689
    [Abstract] [Full Text] [Related]

  • 8. Rofecoxib 50 mg and valdecoxib 20 or 40 mg in adults and adolescents with postoperative pain after third molar extraction: results of two randomized, double-blind, placebo-controlled, single-dose studies.
    Daniels SE, Desjardins PJ, Bird SR, Smugar SS, Tershakovec AM.
    Clin Ther; 2006 Jul 24; 28(7):1022-34. PubMed ID: 16990080
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial.
    Emkey R, Rosenthal N, Wu SC, Jordan D, Kamin M, CAPSS-114 Study Group.
    J Rheumatol; 2004 Jan 24; 31(1):150-6. PubMed ID: 14705234
    [Abstract] [Full Text] [Related]

  • 10. Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.
    Goldstein JL, Bello AE, Spalding W, Suh S, Fort JG.
    J Rheumatol; 2005 Jan 24; 32(1):111-7. PubMed ID: 15630735
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults.
    Kivitz A, Fairfax M, Sheldon EA, Xiang Q, Jones BA, Gammaitoni AR, Gould EM.
    Clin Ther; 2008 Dec 24; 30(12):2366-77. PubMed ID: 19167595
    [Abstract] [Full Text] [Related]

  • 12. A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis.
    Kivitz AJ, Espinoza LR, Sherrer YR, Liu-Dumaw M, West CR.
    Semin Arthritis Rheum; 2007 Dec 24; 37(3):164-73. PubMed ID: 17570469
    [Abstract] [Full Text] [Related]

  • 13. Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors.
    Detora LM, Krupa D, Bolognese J, Sperling RS, Ehrich EW.
    J Rheumatol; 2001 Nov 24; 28(11):2494-503. PubMed ID: 11708424
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials.
    Katz N, Ju WD, Krupa DA, Sperling RS, Bozalis Rodgers D, Gertz BJ, Gimbel J, Coleman S, Fisher C, Nabizadeh S, Borenstein D, Vioxx Chronic Low Back Pain Study Group.
    Spine (Phila Pa 1976); 2003 May 01; 28(9):851-8; discussion 859. PubMed ID: 12941996
    [Abstract] [Full Text] [Related]

  • 15. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.
    Ehrich EW, Schnitzer TJ, McIlwain H, Levy R, Wolfe F, Weisman M, Zeng Q, Morrison B, Bolognese J, Seidenberg B, Gertz BJ.
    J Rheumatol; 1999 Nov 01; 26(11):2438-47. PubMed ID: 10555907
    [Abstract] [Full Text] [Related]

  • 16. Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee.
    Karlsson J, Pivodic A, Aguirre D, Schnitzer TJ.
    J Rheumatol; 2009 Jun 01; 36(6):1290-7. PubMed ID: 19411388
    [Abstract] [Full Text] [Related]

  • 17. A randomized controlled study comparing rofecoxib, diclofenac sodium, and placebo in post-bunionectomy pain.
    Desjardins PJ, Black PM, Daniels S, Bird SR, Fitzgerald BJ, Petruschke RA, Tershakovec A, Chang DJ.
    Curr Med Res Opin; 2004 Oct 01; 20(10):1523-37. PubMed ID: 15462686
    [Abstract] [Full Text] [Related]

  • 18. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.
    Daniels S, Robbins J, West CR, Nemeth MA.
    Clin Ther; 2009 Jun 01; 31(6):1192-208. PubMed ID: 19695387
    [Abstract] [Full Text] [Related]

  • 19. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.
    Schwartz JI, Vandormael K, Malice MP, Kalyani RN, Lasseter KC, Holmes GB, Gertz BJ, Gottesdiener KM, Laurenzi M, Redfern KJ, Brune K.
    Clin Pharmacol Ther; 2002 Jul 01; 72(1):50-61. PubMed ID: 12152004
    [Abstract] [Full Text] [Related]

  • 20. Pain management in osteoarthritis: a focus on onset of efficacy--a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials.
    Battisti WP, Katz NP, Weaver AL, Matsumoto AK, Kivitz AJ, Polis AB, Geba GP.
    J Pain; 2004 Nov 01; 5(9):511-20. PubMed ID: 15556830
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.